BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia (CML), was presented in a poster at the Annual Meeting of the American Society of Hematology (ASH 2013). BGB324 was effective in treating animals infected with CML cells expressing the T315I mutation of ABL.
BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia
2015, Journal Blood
Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia
December 17, 2013, News Medical
Data Highlights BGB324 As A Potential Novel Treatment Option For Drug Resistant Chronic Myeloid
December 17, 2013, The Street